Do analysts recommend EGRX or HCWB?

HCW Biologics has a consensus target price of $30.00, indicating a potential upside of 597.67%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts plainly believe HCW Biologics is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate DYAI or EGRX?

Dyadic International presently has a consensus price target of $3.00, indicating a potential upside of 218.98%. Given Dyadic International's stronger consensus rating and higher probable upside, equities analysts clearly believe Dyadic International is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VIRI or EGRX more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Eagle Pharmaceuticals N/A N/A N/A

Do analysts rate EGRX or SNTI?

Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 834.58%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is EGRX or SNTI more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Senti Biosciences N/A -532.05% -103.35%

Do analysts rate EGRX or KALA?

KALA BIO has a consensus price target of $1,018.75, suggesting a potential upside of 60,539.88%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is EGRX or KALA more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A KALA BIO N/A -1,336.10% -94.85%

Eagle Pharmaceuticals (EGRX) Competitors

$0.67 0.00 (0.00%)

As of 07/2/2026

Compare

EGRX vs. HCWB, DYAI, VIRI, SNTI, and KALA

Should you buy Eagle Pharmaceuticals stock or one of its competitors? MarketBeat compares Eagle Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eagle Pharmaceuticals include HCW Biologics (HCWB), Dyadic International (DYAI), Virios Therapeutics (VIRI), Senti Biosciences (SNTI), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry.

How does Eagle Pharmaceuticals compare to HCW Biologics?

Eagle Pharmaceuticals (NASDAQ:EGRX) and HCW Biologics (NASDAQ:HCWB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

In the previous week, HCW Biologics had 4 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 4 mentions for HCW Biologics and 0 mentions for Eagle Pharmaceuticals. HCW Biologics' average media sentiment score of 0.50 beat Eagle Pharmaceuticals' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
HCW Biologics	Neutral

Eagle Pharmaceuticals has a net margin of 0.00% compared to HCW Biologics' net margin of -34.73%. Eagle Pharmaceuticals' return on equity of 0.00% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
HCW Biologics	-34.73%	-486.87%	-29.19%

Eagle Pharmaceuticals has higher revenue and earnings than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.57
HCW Biologics	$50K	137.60	-$7.96M	-$56.75	N/A

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.0% of HCW Biologics shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 9.1% of HCW Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

HCW Biologics has a consensus target price of $30.00, indicating a potential upside of 597.67%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts plainly believe HCW Biologics is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, HCW Biologics has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market.

Summary

Eagle Pharmaceuticals beats HCW Biologics on 9 of the 16 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Dyadic International?

Dyadic International (NASDAQ:DYAI) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

In the previous week, Dyadic International had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for Dyadic International and 0 mentions for Eagle Pharmaceuticals. Dyadic International's average media sentiment score of 0.00 equaled Eagle Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Dyadic International	Neutral
Eagle Pharmaceuticals	Neutral

Eagle Pharmaceuticals has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Eagle Pharmaceuticals' return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
Eagle Pharmaceuticals	N/A	N/A	N/A

Dyadic International presently has a consensus price target of $3.00, indicating a potential upside of 218.98%. Given Dyadic International's stronger consensus rating and higher probable upside, equities analysts clearly believe Dyadic International is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eagle Pharmaceuticals has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	11.09	-$7.36M	-$0.23	N/A
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.57

Dyadic International has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Eagle Pharmaceuticals beats Dyadic International on 9 of the 15 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Eagle Pharmaceuticals' return on equity of 0.00% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Eagle Pharmaceuticals	N/A	N/A	N/A

Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Eagle Pharmaceuticals has higher revenue and earnings than Virios Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.57

In the previous week, Virios Therapeutics had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for Virios Therapeutics and 0 mentions for Eagle Pharmaceuticals. Virios Therapeutics' average media sentiment score of 0.00 equaled Eagle Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Eagle Pharmaceuticals	Neutral

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Eagle Pharmaceuticals beats Virios Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Senti Biosciences?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Eagle Pharmaceuticals has higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.57
Senti Biosciences	$20K	1,666.53	-$61.44M	-$1.92	N/A

Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 834.58%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Senti Biosciences is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Senti Biosciences had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for Eagle Pharmaceuticals. Senti Biosciences' average media sentiment score of 0.67 beat Eagle Pharmaceuticals' score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
Senti Biosciences	Positive

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Senti Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Eagle Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

Eagle Pharmaceuticals' return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Senti Biosciences	N/A	-532.05%	-103.35%

Summary

Eagle Pharmaceuticals and Senti Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to KALA BIO?

Eagle Pharmaceuticals (NASDAQ:EGRX) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Eagle Pharmaceuticals has higher revenue and earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.57
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

Eagle Pharmaceuticals' return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
KALA BIO	N/A	-1,336.10%	-94.85%

In the previous week, Eagle Pharmaceuticals' average media sentiment score of 0.00 equaled KALA BIO'saverage media sentiment score.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
KALA BIO	Neutral

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, meaning that its share price is 335% less volatile than the broader market.

KALA BIO has a consensus price target of $1,018.75, suggesting a potential upside of 60,539.88%. Given KALA BIO's stronger consensus rating and higher possible upside, analysts plainly believe KALA BIO is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Eagle Pharmaceuticals beats KALA BIO on 9 of the 12 factors compared between the two stocks.

Get Eagle Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EGRX vs. The Competition

Export

Metric	Eagle Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.70M	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	0.57	1.66	28.02	24.70
Price / Sales	0.03	127.11	540.37	99.49
Price / Cash	0.40	20.06	49.26	57.09
Price / Book	N/A	8.17	10.96	6.46
Net Income	$35.64M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	11.67%	4.41%	5.25%	3.81%
1 Year Performance	-77.67%	49.43%	33.29%	23.90%

Eagle Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EGRX Eagle Pharmaceuticals	N/A	$0.67 flat	N/A	N/A	$8.70M	$257.55M	0.57	100
HCWB HCW Biologics	4.1167 of 5 stars	$4.85 -2.9%	$30.00 +519.1%	-82.9%	$34.69M	$50K	N/A	40	Stock Split
DYAI Dyadic International	2.4082 of 5 stars	$0.94 +5.2%	$3.00 +218.1%	+1.0%	$34.36M	$3.09M	N/A	7	Gap Up
VIRI Virios Therapeutics	N/A	$1.78 +7.9%	N/A	-69.0%	$34.28M	N/A	N/A	5	Gap Up
SNTI Senti Biosciences	2.6954 of 5 stars	$1.10 -0.5%	$10.00 +813.2%	-52.8%	$34.11M	$20K	N/A	4	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EGRX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. HCWB, DYAI, VIRI, SNTI, and KALA

How does Eagle Pharmaceuticals compare to HCW Biologics?

Summary

How does Eagle Pharmaceuticals compare to Dyadic International?

Summary

How does Eagle Pharmaceuticals compare to Virios Therapeutics?

Summary

How does Eagle Pharmaceuticals compare to Senti Biosciences?

Summary

How does Eagle Pharmaceuticals compare to KALA BIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. HCWB, DYAI, VIRI, SNTI, and KALA

How does Eagle Pharmaceuticals compare to HCW Biologics?

Does the media favor EGRX or HCWB?

Is EGRX or HCWB more profitable?

Which has better earnings & valuation, EGRX or HCWB?

Do institutionals & insiders believe in EGRX or HCWB?

Do analysts recommend EGRX or HCWB?

Which has more risk and volatility, EGRX or HCWB?

Summary

How does Eagle Pharmaceuticals compare to Dyadic International?

Does the media refer more to DYAI or EGRX?

Is DYAI or EGRX more profitable?

Do analysts rate DYAI or EGRX?

Which has better earnings & valuation, DYAI or EGRX?

Which has more risk and volatility, DYAI or EGRX?

Do institutionals & insiders have more ownership in DYAI or EGRX?

Summary

How does Eagle Pharmaceuticals compare to Virios Therapeutics?

Is VIRI or EGRX more profitable?

Which has more risk and volatility, VIRI or EGRX?

Which has higher earnings and valuation, VIRI or EGRX?

Does the media prefer VIRI or EGRX?

Do insiders & institutionals hold more shares of VIRI or EGRX?

Summary

How does Eagle Pharmaceuticals compare to Senti Biosciences?

Which has preferable valuation and earnings, EGRX or SNTI?

Do analysts rate EGRX or SNTI?

Does the media refer more to EGRX or SNTI?

Do insiders & institutionals hold more shares of EGRX or SNTI?

Which has more risk & volatility, EGRX or SNTI?

Is EGRX or SNTI more profitable?

Summary

How does Eagle Pharmaceuticals compare to KALA BIO?

Which has higher valuation & earnings, EGRX or KALA?

Is EGRX or KALA more profitable?

Does the media refer more to EGRX or KALA?

Do institutionals and insiders have more ownership in EGRX or KALA?

Which has more risk and volatility, EGRX or KALA?

Do analysts rate EGRX or KALA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools